MedTrace Logo

Colchicine for Patients With Chagas´ Disease( B1 Stage)

NCT03704181 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2019-03-11

No results posted yet for this study

Summary

This study evaluate the addition of colchicine in the treatment of patients with Chagas´disease.

Forty patients will receive colchicine while twenty patients will receive placebo

Conditions

  • Chagas Disease
  • Colchicine Resistance

Interventions

DRUG

Colchicine 0.5 MG twice day for one year

placebo twice day for one year

DRUG

Placebo Oral Tablet

placebo twice day for one year

Sponsors & Collaborators

  • Fundação de Amparo à Pesquisa do Estado de São Paulo

    collaborator OTHER_GOV

  • University of Sao Paulo General Hospital

    lead OTHER

Principal Investigators

  • Fabio Fernandes, Md, PHD · Heart Institute, University of São Paulo

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-01
Primary Completion
2020-12-30
Completion
2021-01-05

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03704181 on ClinicalTrials.gov